KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion

Journal of Clinical Pathology

Volumn 63, Issue 7, 2010, Pages 604-608

  Stewart, C J R ^a   Amanuel, B ^b   Grieu, F ^b   Carrello, A ^b   Iacopetta, B ^c  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICROSATELLITE INSTABILITY; MYOMETRIUM; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; CELL DIFFERENTIATION; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; MYOMETRIUM; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 77955745245     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.069500     Document Type: Article

References (55)

1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005:366:491-505.
2. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111:436-47.
3. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002;110:673-89.
4. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77. (Pubitemid 32601237)
5. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;29:4783-91.
6. Prat J, Gallardo A, Cuatrecasas M, Catasus L. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72-87.
7. Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutical view points. J Clin Pathol. Published Online First: 31 October 2008. doi:10.1136/jcp.2008.056101.
8. Saegusa M, Okayasu I. Frequent nuclear β-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001;194:59-67.
9. Brachtel EF, Sanchez-Estevez C, Moreno-Bueno G, et al. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol 2005;29:1322-9. (Pubitemid 41368768)
10. Shia J, Black D, Hummer AJ, et al. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 2008;39:116-25. (Pubitemid 350216167)
11. Garg K, Soslow RA. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 2009;62:679-84.
12. Karamurzin Y, Rutgers JKL. DNA mismatch repair deficiency in endometrial carcinoma. Int J Gynecol Pathol 2009;28:239-55.
13. Longacre T, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am J Surg Pathol 1999;23:69-78. (Pubitemid 29025242)
14. Suzuki C, Matsumoto T, Sonoue H, et al. Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium. Pathol Int 2003;53:495-500. (Pubitemid 37076289)
15. Clement PB, Young RH. Atlas of gynecologic surgical pathology. 2nd edn. Philadelphia: Elsevier Saunders, 2008:161-93.
16. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 2003;22:324-33.
17. Stewart CJR, Brennan BA, Leung YC, et al. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009;41:471-6.
18. Stewart CJR, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 2009;55:91-101.
19. Stewart CJR, Crook ML, Leung YC, et al. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod Pathol 2009:22:725-33.
20. Stewart CJR, Crook ML, Doherty DA. Micro-anatomical variation in cellular proliferation in endometrial adenocarcinoma, and inverse correlation between Ki-67 and cytokeratin 7 expression. Histopathology (In press).
21. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-18. (Pubitemid 46897605)
22. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
23. Hugo H, Ackland ML, Blick T, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-83. (Pubitemid 47509716)
24. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004;14:105-14.
25. Mammas IN, Zafiropoulos A, Spandidos DA. Involvement of the ras genes in female genital tract cancer. Int J Oncol 2005;26:1241-5.
26. Giehl K. Oncogenic ras in tumour progression and metastases. Biol Chem 2005;386:193-205. (Pubitemid 40485425)
27. Prall F, Ostwald C. High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. Hum Pathol 2007;38:1696-702. (Pubitemid 47589093)
28. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-90. (Pubitemid 46194105)
29. Feng Y-Z, Shiozawa T, Miyamoto T, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005;11:6133-38. (Pubitemid 41262939)
30. Duggan BD, Felix JC, Muderspach LI, et al. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-21.
31. Lagarda H, Catasus L, Arguelles R, et al. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-99. (Pubitemid 32118131)
32. Soong R, Iacopetta B. A rapid and non-isotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathology 1997;10:252-8 (Pubitemid 27130464)
33. Iacopetta B, Grieu F. Routine detection of the replication error phenotype in clinical tumor specimens using fluorescence-SSCP. Biotechniques 2000;28:566-70. (Pubitemid 30140464)
34. Wang C, van Rijnsoever M, Grieu F, et al. Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 2003;64:259-65. (Pubitemid 36438811)
35. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006;5:2.
36. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-52.
37. Tsuda H, Jiko K, Yajima M, et al. Frequent occurrence of c-Ki-ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Int J Gynecol Pathol 1995;14:255-9.
38. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer 2000;88:814-24.
39. Mutch DG, Powell MA, Mallon MA, et al. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. Am J Obstet Gynecol 2004;190:935-42.
40. Salvesen HB, Kumar R, Stefansson I, et al. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer 2005;115:930-4.
41. Pappa KI, Choleza M, Markaki S, et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol 2006;100:596-600. (Pubitemid 43246877)
42. Kang S, Lee JM, Jeon E-S, et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer 2006;119:1316-21. (Pubitemid 44258806)
43. Kawaguchi M, Yanokura M, Banno K, et al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J Onol 2009;34:1541-7.
44. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005;15:97-101.
45. Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 2006;63:449-68.
46. Janda E, Lehmann K, Killisch I, et al. Ras and TGFb cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156;299-313. (Pubitemid 34839911)
47. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-58. (Pubitemid 41267170)
48. Pijnenborg JMA, Dam-de Veen GC, Kisters N, et al. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. Ann Oncol 2007;18:491-7. (Pubitemid 46359628)
49. Pallares J, Velasco A, Eritja N, et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 2008;21:691-9. (Pubitemid 351744834)
50. Mutter GL, Wada H, Faquin WC, et al. KRAS mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. J Clin Pathol: Mol Pathol 1999;52:257-62. (Pubitemid 29469917)
51. Esteller M, Garcia A, Martinez-Palones JM, et al. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer 1997;33:1572-7. (Pubitemid 28123477)
52. Sakamoto T, Murase T, Urushibata H, et al. Microsatellite instability and somatic mutations in endometrial carcinomas. Gynecol Oncol 1998;71:53-8. (Pubitemid 28492393)
53. Swisher E, Peiffer-Schneider S, Mutch D, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 1999;85:119-26. (Pubitemid 29031365)
54. Ortega E, Marti RM, Yeramian A, et al. Targeted therapies in gynecological cancers and melanoma. Semin Diagn Pathol 2008;25:262-73.
55. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009;16:8-13.